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Editorial on the Research Topic
Role of Nrf2 in Disease: Novel Molecular Mechanisms and Therapeutic Approaches
Oxidative stress and inflammation are pathological processes involved in the genesis and 
development of numerous disorders. Nuclear factor erythroid 2–related factor 2 (Nrf2) is a 
transcription factor that regulates the expression of multiple antioxidant and cytoprotective 
proteins and enzymes, thus playing a key role in protection against oxidative damage. There 
is a growing interest in understanding the specific role of Nrf2 in the development and 
progression of diseases as well as design novel approaches targeting Nrf2 to prevent and/or 
retard tissue injury.
This special issue contains 16 papers, including 7 original research articles and 9 reviews, 
reporting important data about the key role of Nrf2 in different pathological conditions.
In the article entitled “Nrf2 as a potential mediator of cardiovascular risk in metabolic 
diseases” by da Costa et al., a reduction in Nrf2 activity in diabetes, obesity, and atherosclerosis, 
thus increasing cardiovascular risk, was described. Importantly, systemic administration of 
specific Nrf2 inducers provided beneficial effects in cardiovascular diseases (da Costa et al.). 
In this sense, a wide range of natural products are promising therapeutic approaches to reduce 
atherogenesis progression by targeting the Nrf2 signaling pathway. These compounds activate 
Nrf2 by multiple mechanisms, such as targeting cysteine residues of Keap-1, disturbance of 
Nrf2/Keap1 interaction, epigenetic modification, and activation of protein kinases pathways. 
The beneficial effects of bioactive compounds are related to a reduction in reactive oxygen 
species (ROS) production, augmentation of glutathione levels, inhibition of nuclear factor 
kappa B inflammatory signaling pathway, and lowering foam cell production (Ooi et al.). Nrf2 
activation endows antioxidant defense and reduces atherosclerosis risk in diabetes, where 
vascular lesions are a common complication of this disease. Tert-butyl hydroquinone (tBHQ) 
increased Nrf2 activation in vascular smooth cells and macrophages. Treatment with tBHQ 
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decrease the size and extension of the atheroma plaque, 
besides lipid content, inflammation, foam cell size, and 
chemokine expression. An increase in the autophagic flux 
in the aorta and an upregulation of autophagy-related 
molecules after tBHQ treatment were also observed (Lazaro 
et al.). Another complication of chronic hyperglycemia is 
related to cognitive dysfunction. Nrf2 is involved in cellular 
homeostasis during diabetes mellitus. Astaxanthin, a potent 
antioxidant, exerted a protective effect on cognitive function 
through the inhibition of oxidative stress and inflammatory 
responses by the elevation of the Nrf2 antioxidant responsive 
element signaling pathway in the brains of chronic diabetic 
rats (Feng et al.). Nrf2 activation has been proposed as an 
antidiabetic strategy. In this context, naringenin, a bioactive 
flavonoid found in citrus fruits, protected pancreatic beta 
cells from oxidative damage in vitro and in streptozotocin-
induced diabetic mice by activating Nrf2. Naringenin 
treatment decreased blood glucose levels, normalized lipid 
profile, restored insulin expression, promoted glycolysis, and 
inhibited gluconeogenesis in streptozotocin-induced diabetic 
mice (Rajappa et al.).
Oxidative stress and inflammation play a key role in the 
central nervous system physiology and pathophysiology of 
different diseases. The brain is highly susceptible to oxidative 
damage, so modulation of Nrf2 is important to provide 
beneficial effects in cerebrovascular diseases like ischemic 
stroke (Liu et al.). Free radical accumulation, due to impaired 
cellular antioxidant defenses or excessive production, results in 
neurotoxicity and cell death. Aging leads to a gradual increase 
in brain oxidative stress, which is accompanied by reduced 
antioxidant defenses, and a reduction in Nrf2 activity. Nrf2 
could be modulated by dietary interventions (dietary energy 
restriction and high energy consumption) in animal models 
of neurological disorders, which leads to improving cognitive 
function, metabolic health, and longevity (Vasconcelos et al.). 
As oxidative stress is an important contributor of age-related 
macular degeneration, an increase in the antioxidant defenses 
can provide novel therapeutic strategies for this disease. 
Beneficial effects of Nrf2 activation have been described in 
retinal cells exposed to different types of oxidative stress 
inductors, so several natural and synthetic activators of Nrf2 
have been tested as effective therapeutic agents for age-related 
macular degeneration (Bellezza).
Depression is a heterogeneous mood disorder characterized 
by mood alterations, social withdrawal, feelings of guilt, low 
self-esteem, anhedonia, idiopathic pain, loss of interest in 
enjoyable activities, and suicidal tendencies. Clinical and 
preclinical studies have revealed that oxidative stress and 
increased activity of immune factor cascades play significant 
roles in the pathophysiology of depression. Different studies 
published in this special issue have outlined the participation 
of Keap1-Nrf2 axis in depression (Hashimoto) and the role 
of quinolinic acid, an N-methyl-D-aspartate agonist, a 
pro-oxidant factor that reduce Nrf2 activity in depression 
(Bansal et al.).
Oxidative stress and inflammation are also a common 
feature of painful diseases. ROS are generated by enzymes of 
immune and nonimmune cells as part of protective actions. In 
this context, Staurengo-Ferrari et al. reviewed the involvement 
of Nrf2 in the mechanisms of action of classic analgesic 
and anti-inflammatory drugs, as well as natural products 
and other molecules that modulate Nrf2, in preclinical and 
clinical stages (Staurengo-Ferrari et al.). Chronic neuropathic 
pain is associated with anxiety- and depressive-like disorders. 
Interestingly, administration of sulforaphane (SFN), a Nrf2 
inductor, had antinociceptive, anxiolytic, and antidepressant 
effects after the induction of persistent neuropathic 
pain (chronic constriction injury of the sciatic nerve) by 
normalizing oxidative stress and inhibiting microglial 
activation, which goes along with by the normalization of 
several biochemical parameters in the spinal cord. Moreover, 
SFN potentiated the antiallodynic effect of morphine 
(Ferreira-Chamorro et al.). In another article, administration 
of SFN 30 min before spared nerve injury surgery significantly 
reduced mechanical withdrawal threshold scores and sucrose 
preference, and restored tissue Keap1 and Nrf2 levels. This 
study suggests that decreased Keap1-Nrf2 signaling in the 
medial prefrontal cortex, hippocampus, and muscle may 
contribute to anhedonia susceptibility and that SFN exerts 
beneficial effects by normalization of decreased Keap1-Nrf2 
signaling (Li et al.).
In another review submitted to this special issue, different 
therapeutic approaches for improving the prognosis of liver 
diseases, including acute liver failure, alcoholic and nonalcoholic 
fatty liver disease, viral hepatitis, and hepatocellular carcinoma 
by targeting hepatic Nrf2 are extensively described (Xu 
et  al.). Besides liver diseases, Nrf2 activators can be used as 
potential therapies for other inflammatory disorders. For 
example, dinardokanshone C, a new compound isolated 
from the roots of Nardostachys chinensis, suppressed the 
induction of inflammatory markers such as cyclooxygenase 2, 
prostaglandin E2, tumor necrosis factor alpha, and interleukin 
6 in lipopolysaccharide-stimulated macrophages, inhibiting 
M1 phenotype and ROS production, through the activation of 
Nrf2 pathway (Luo et al.).
Finally, the article by Rubio-Navarro et al. described that 
Nrf2 also plays an important role in renal protection against 
oxidative stress in renal diseases (Rubio-Navarro et al.). Massive 
intravascular hemolysis induces acute kidney injury. In this 
context, hemoglobin is accumulated in the kidney, inducing 
oxidative stress, inflammation, and tubular cell death. It has 
been demonstrated that Nrf2 plays an important role against 
hemoglobin-mediated renal damage. Thus, Nrf2 deficiency 
produces an increase in renal injury, loss of kidney function, 
oxidative and reticulum endoplasmic stress, and cell death. 
Moreover, Nrf2 activation by SFN treatment protected both in 
vivo and in vitro against hemoglobin toxicity.
In summary, this special issue will help to understand the 
important role of Nrf2 in disease. The articles published in this 
special issue show novel molecular mechanisms involved in 
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Nrf2-mediated tissue protection as well as possible therapeutic 
approaches to decrease organ injury.
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